Publications by authors named "Daniela Montes-Berrueta"
Article Synopsis
- The study explores new mRNA vaccine strategies to enhance effectiveness against COVID-19, focusing on specific protein domains of the virus instead of the full-length spike protein.
- The candidate vaccine mRNA-1283, combining the N-terminal domain and receptor binding domain, shows better antigen expression, stronger antibody responses, and improved stability compared to existing vaccines.
- In animal tests, mRNA-1283 elicits equal or greater immune protection against various COVID-19 variants, supporting its advancement to clinical trials for further evaluation.
Article Synopsis
- * Researchers tested two new bivalent vaccines (mRNA-1273.214 and mRNA-1273.222) in mice and found they produced stronger antibody responses against Omicron variants compared to the original vaccine.
- * Administering these bivalent vaccines as boosters significantly improved immune protection and reduced lung infection severity in mice, highlighting their potential effectiveness against circulating strains.
Article Synopsis
- The emergence of SARS-CoV-2 variants in the Omicron lineage has led to reduced vaccine effectiveness and ongoing virus transmission due to the spike protein's ability to evade antibodies.
- Researchers evaluated two bivalent vaccines that include mRNAs for spike proteins from both the original virus and recent variants (BA.1 or BA.4/5) and found they produced stronger immune responses in mice compared to existing monovalent vaccines.
- When used as a booster after initial vaccination, these bivalent vaccines not only generated a more robust antibody response but also provided greater protection against BA.5 infections and reduced inflammation in the lungs.
Article Synopsis
- Researchers developed a new mRNA vaccine, mRNA-1283, targeting specific spike protein domains of the virus responsible for COVID-19.
- This vaccine demonstrated enhanced antigen expression, antibody responses, and stability when stored in refrigerated conditions compared to the existing mRNA-1273 vaccine.
- In preclinical tests, mRNA-1283 provided similar or better immune protection against various COVID-19 variants in mice, indicating its potential for human clinical trials.
Article Synopsis
- The rise of SARS-CoV-2 in 2019 prompted the creation of numerous vaccines, with several now approved for human use.
- Monitoring how well these vaccines generate antibody responses against new variants is crucial for shaping public health strategies.
- Research indicates that neutralizing antibody responses in vaccinated mice are not as effective or representative as those in humans or non-human primates, highlighting possible limitations of using mice in these studies.
The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.
View Article and Find Full Text PDFWe have used an insertional mutagenesis approach to generate new C. reinhardtii motility mutants. Of 56 mutants isolated, one is a new allele at the ODA3 locus, called oda3-6.
View Article and Find Full Text PDFNef -HIV-1 has been shown to be involved in NADPH complex interaction and superoxide production. The aim of this work was to study the domains involved in the interaction between Nef and p22-phox. Two approaches were used: 1) in silico modelling, to determine the potential binding motifs and design Nef truncated forms and 2) functional assays.
View Article and Find Full Text PDFAbstract. Chronic Granulomatous Disease (CGD) is a primary immunodeficiency characterized by defects in superoxide (O2-) production, which result from mutations in one of the four NADPH oxidase components, predisposing to bacterial and fungal infections. Besides the O2-defect, it has been described that neutrophils from CGD patients are resistant to cell death, a phenomenon that has been connected to chronic inflammation and predisposition to autoimmune diseases.
View Article and Find Full Text PDF